| 51 |
26666244 | A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. | 2016 Apr |
1 |
| 52 |
26683364 | Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. | 2016 Feb 2 |
2 |
| 53 |
26837474 | Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1). | 2016 Mar |
2 |
| 54 |
26912134 | A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. | 2016 Feb 24 |
2 |
| 55 |
27100819 | Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. | 2016 Jun 1 |
1 |
| 56 |
27168466 | The role of the RAS pathway in iAMP21-ALL. | 2016 Sep |
1 |
| 57 |
27196001 | MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. | 2016 |
1 |
| 58 |
27231576 | A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. | 2016 |
3 |
| 59 |
27467210 | Selumetinib in the treatment of non-small-cell lung cancer. | 2016 Nov |
3 |
| 60 |
27469379 | Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. | 2016 Aug |
1 |
| 61 |
27494873 | Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. | 2016 Aug 30 |
1 |
| 62 |
27523799 | Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS/MS. | 2016 Sep |
1 |
| 63 |
27751676 | Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects. | 2016 Nov |
1 |
| 64 |
27769200 | Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells. | 2016 Oct 21 |
1 |
| 65 |
28029918 | Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. | 2016 Dec 29 |
2 |
| 66 |
25268371 | A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. | 2015 Jan 6 |
2 |
| 67 |
25348516 | Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. | 2015 Jan 15 |
2 |
| 68 |
25385055 | Selumetinib for the treatment of cancer. | 2015 Jan |
1 |
| 69 |
25516890 | Antitumor activity in RAS-driven tumors by blocking AKT and MEK. | 2015 Feb 15 |
1 |
| 70 |
25637165 | Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. | 2015 Jun |
1 |
| 71 |
25887099 | A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. | 2015 Jul |
2 |
| 72 |
25892646 | Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. | 2015 Jul |
1 |
| 73 |
25959272 | EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. | 2015 Dec |
1 |
| 74 |
26059332 | Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). | 2015 Jun 10 |
2 |
| 75 |
26360058 | Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia. | 2015 |
1 |
| 76 |
26571380 | Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. | 2015 |
2 |
| 77 |
26622906 | Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells. | 2015 Oct |
1 |
| 78 |
24178622 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. | 2014 Jan 15 |
1 |
| 79 |
24363449 | Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. | 2014 Feb 15 |
2 |
| 80 |
24567366 | DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. | 2014 May |
1 |
| 81 |
24812410 | Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. | 2014 Jul 15 |
1 |
| 82 |
24935174 | Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. | 2014 Nov |
1 |
| 83 |
24938562 | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. | 2014 Jun 18 |
1 |
| 84 |
24938872 | MEK inhibitor effective against proliferation in breast cancer cell. | 2014 Sep |
1 |
| 85 |
24939055 | Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. | 2014 Jun 17 |
2 |
| 86 |
25253770 | Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. | 2014 Nov 27 |
2 |
| 87 |
25275595 | Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. | 2014 Oct 2 |
1 |
| 88 |
25278770 | Profile of selumetinib and its potential in the treatment of melanoma. | 2014 |
1 |
| 89 |
25294906 | MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. | 2014 Dec 1 |
1 |
| 90 |
25379021 | Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. | 2014 Oct |
3 |
| 91 |
22565394 | Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. | 2013 Feb |
1 |
| 92 |
23200175 | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. | 2013 Jan |
1 |
| 93 |
23234544 | The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. | 2013 Mar 1 |
3 |
| 94 |
23261356 | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. | 2013 Feb |
1 |
| 95 |
23406027 | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. | 2013 Feb 14 |
2 |
| 96 |
23414467 | Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. | 2013 Feb |
1 |
| 97 |
23530058 | MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. | 2013 Jun |
1 |
| 98 |
23588995 | MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands. | 2013 Jun |
2 |
| 99 |
23735514 | Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. | 2013 Jul |
1 |
| 100 |
23757356 | Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. | 2013 Aug 1 |
1 |